169 related articles for article (PubMed ID: 38471356)
21. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
22. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
24. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM).
Kobayashi Y
Int J Hematol; 2019 Nov; 110(5):524-528. PubMed ID: 31494831
[No Abstract] [Full Text] [Related]
25. [New developments in Waldenström's macroglobulinemia].
Grunenberg A; Buske C
Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176
[TBL] [Abstract][Full Text] [Related]
26. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
27. How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.
Baron M; Simon L; Poulain S; Leblond V
Curr Oncol Rep; 2019 Feb; 21(3):27. PubMed ID: 30806816
[TBL] [Abstract][Full Text] [Related]
28. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
29. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
30. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
31. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
32. [How can we treat Waldenström's macroglobulinemia?].
Mucsi AO; Nagy Z
Magy Onkol; 2017 Mar; 61(1):12-20. PubMed ID: 28273184
[TBL] [Abstract][Full Text] [Related]
33. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.
Terpos E; Branagan AR; García-Sanz R; Trotman J; Greenberger LM; Stephens DM; Morel P; Kimby E; Frustaci AM; Hatjiharissi E; San-Miguel J; Dimopoulos MA; Treon SP; Leblond V
Semin Hematol; 2023 Mar; 60(2):107-112. PubMed ID: 37099029
[TBL] [Abstract][Full Text] [Related]
34. A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia.
Patel D; Sidana M; Mdluli X; Patel V; Stapleton A; Dasanu CA
J Oncol Pharm Pract; 2022 Dec; 28(8):1917-1921. PubMed ID: 35306909
[TBL] [Abstract][Full Text] [Related]
35. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
36.
Alcoceba M; García-Álvarez M; Medina A; Maldonado R; González-Calle V; Chillón MC; Sarasquete ME; González M; García-Sanz R; Jiménez C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628381
[TBL] [Abstract][Full Text] [Related]
37. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
[TBL] [Abstract][Full Text] [Related]
38. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
Grunenberg A; Buske C
Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
[TBL] [Abstract][Full Text] [Related]
39. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
Treon SP; Tedeschi A; San-Miguel J; Garcia-Sanz R; Anderson KC; Kimby E; Minnema MC; Benevolo G; Qiu L; Yi S; Terpos E; Tam CS; Castillo JJ; Morel P; Dimopoulos M; Owen RG
Semin Hematol; 2023 Mar; 60(2):97-106. PubMed ID: 37173155
[TBL] [Abstract][Full Text] [Related]
40. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]